Dianthus Therapeutics Reaches Analyst Target Price
March 25, 2024 at 06:40 AM EDT
In recent trading, shares of Dianthus Therapeutics Inc (DNTH) have crossed above the average analyst 12-month target price of $31.80, changing hands for $31.94/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..